Magazine article Clinical Psychiatry News

Transdermal MAO Inhibitor Appears Safe without Dietary Restrictions

Magazine article Clinical Psychiatry News

Transdermal MAO Inhibitor Appears Safe without Dietary Restrictions

Article excerpt

PHOENIX, ARIZ. -- Selegiline, a selective monoamine oxidase inhibitor, can be used safely in the transdermal form without dietary restrictions, according to controlled data presented at a meeting of the New Clinical Drug Evaluation Unit sponsored by the National Institute of Mental Health.

No difference in adverse effects was seen between patients who received the treatment and those on placebo, said Dr. Jay Amsterdam of the University of Pennsylvania, Philadelphia.

Despite their efficacy in depression, the use of MAO inhibitors has been severely limited by safety issues-in particular, fear of hypertensive reactions associated with the ingestion of tyramine-rich foods.

Selegiline is a MAO-B inhibitor that has been shown to have a significant antidepressant effect at oral doses of 3 0-60 mg/day But at this level, the drug also inhibits MAO-A and requires the restriction of dietary tyramine and sympathomimetic amines. A transdermal delivery system was developed to forestall the danger of severe reactions: It avoids first-pass metabolism (resulting in less metabolite formation) and direct gastrointestinal interaction with MAO-A. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.